Puma Biotechnology (PBYI) PT Lowered to $27 at Cowen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
Go back to Puma Biotechnology (PBYI) PT Lowered to $27 at Cowen
June 5, 2019 7:00 AM EDT
LOS ANGELES--(BUSINESS WIRE)--
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company,
announced that on June 3, 2019 the Compensation Committee of Pumas
Board of Directors approved the grant of inducement restricted stock
unit awards covering an aggregate of 82,063 shares of Puma common stock
to 15 new non-executive employees.
The awards were granted under Pumas 2017 Employment Inducement
Incentive Award Plan, which was adopted on April 27, 2017 and provides
for the granting of equity awards to new... More
June 4, 2019 11:10 AM EDT
LOS ANGELES--(BUSINESS WIRE)--
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company,
announced that results from the Phase III NALA trial of PB272
(neratinib) in patients with HER2-positive metastatic breast cancer who
have failed two or more prior lines of HER2-directed treatments
(third-line disease) in the setting of metastatic disease, were
presented at the American Society of Clinical Oncology (ASCO) 2019
Annual Meeting in Chicago. Neratinib + capecitabine versus lapatinib +
capecitabine in patients with HER2+ metastatic breast cancer previously
treated with 2 HER2-directed regimens: Findings from the
multinational, randomized, phase III NALA trial, was... More
